| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KIR2DL2 |
| Uniprot No | P43627 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-348aa |
| 氨基酸序列 | HEGVHRKPSLLAHPGRLVKSEETVILQCWSDVRFEHFLLHREGKFKDTLHLIGEHHDGVSKANFSIGPMMQDLAGTYRCYGSVTHSPYQLSAPSDPLDIVITGLYEKPSLSAQPGPTVLAGESVTLSCSSRSSYDMYHLSREGEAHECRFSAGPKVNGTFQADFPLGPATHGGTYRCFGSFRDSPYEWSNSSDPLLVSVIGNPSNSWPSPTEPSSKTGNPRHLHILIGTSVVIILFILLFFLLHRWCSNKKNAAVMDQESAGNRTANSEDSDEQDPQEVTYTQLNHCVFTQRKITRPSQRPKTPPTDIIVYAELPNAESRSKVVSCP |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KIR2DL2重组蛋白的3篇模拟参考文献示例(注：内容为虚构，仅供格式参考)：
---
1. **"Structural Insights into KIR2DL2-HLA-C Interaction Using Recombinant Protein Crystallography"**
*作者：Smith A, et al. (Journal of Immunology, 2018)*
**摘要**：通过重组KIR2DL2蛋白的晶体结构解析，揭示了其与HLA-Cw3的精确结合界面，阐明抑制性信号传导的分子机制。
2. **"Recombinant KIR2DL2 Protein Modulates NK Cell Cytotoxicity in Autoimmune Disease Models"**
*作者：Chen L, et al. (Frontiers in Immunology, 2020)*
**摘要**：利用大肠杆菌表达的重组KIR2DL2蛋白，体外实验证明其通过竞争性结合HLA-C，可抑制NK细胞对自身细胞的攻击，为自身免疫治疗提供新策略。
3. **"Development of a SPR-Based Assay for KIR2DL2 Ligand Screening"**
*作者：Garcia R, et al. (Protein Science, 2019)*
**摘要**：构建重组KIR2DL2蛋白的表面等离子体共振(SPR)检测平台，筛选出小分子配体，并验证其调控NK细胞活性的潜在应用。
---
*注：以上文献为示例性质，实际研究中请通过学术数据库检索真实文献。*
KIR2DL2 is a member of the killer cell immunoglobulin-like receptor (KIR) family, which plays a critical role in regulating natural killer (NK) cell activity and adaptive immune responses. These receptors are expressed primarily on NK cells and a subset of T lymphocytes, where they interact with major histocompatibility complex (MHC) class I molecules on target cells. KIR2DL2. specifically, is an inhibitory receptor characterized by two extracellular immunoglobulin-like domains (D0 and D2) and a long cytoplasmic tail containing immunoreceptor tyrosine-based inhibitory motifs (ITIMs). It recognizes HLA-C group 1 (HLA-C1) allotypes, such as HLA-Cw*03. *07. and *15. transmitting inhibitory signals to suppress NK cell cytotoxicity upon binding. This interaction ensures immune tolerance to healthy cells while enabling NK cells to detect and eliminate stressed or infected cells that downregulate MHC-I.
Recombinant KIR2DL2 proteins are engineered to study receptor-ligand interactions, signaling mechanisms, and therapeutic applications. Produced via heterologous expression systems (e.g., mammalian, insect, or bacterial cells), these proteins retain structural and functional properties of native KIR2DL2. They are purified using affinity chromatography and often tagged (e.g., Fc-fusion, His-tag) for detection or immobilization. Recombinant KIR2DL2 is widely used in structural studies (e.g., crystallography), binding assays with HLA-C variants, and functional analyses of NK cell inhibition. Clinically, it aids in developing immunotherapies targeting KIR-HLA pathways in cancers, autoimmune disorders, and pregnancy complications. Polymorphisms in KIR2DL2 have been linked to disease outcomes, including viral susceptibility (e.g., HIV, hepatitis C) and graft rejection, underscoring its therapeutic relevance. Research on recombinant KIR2DL2 continues to advance precision immunology and drug discovery.
×
